MarketCap
Facebook
X
TelegramQuartalsbericht 2022-Q3
hinzugefügt 07.11.2022
AVEO Pharmaceuticals Gesamtes Eigenkapital 2011-2026 | AVEO
Gesamtes Eigenkapital Jährlich AVEO Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 45.9 M | 35.3 M | 14.8 M | -27.2 M | -40.8 M | -1.92 M | 17.2 M | 20.6 M | 69.9 M | 119 M | 224 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 224 M | -40.8 M | 43.3 M |
Gesamtes Eigenkapital Vierteljährlich AVEO Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 28.8 M | 30.6 M | 36.9 M | 45.9 M | 51.2 M | 60.2 M | 72.6 M | 35.3 M | 35.3 M | 35.3 M | 35.3 M | 14.8 M | 14.8 M | 14.8 M | 14.8 M | -27.2 M | -27.2 M | -27.2 M | -27.2 M | -40.8 M | -40.8 M | -40.8 M | -40.8 M | -1.92 M | -1.92 M | -1.92 M | -1.92 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 20.6 M | 20.6 M | 20.6 M | 20.6 M | 69.9 M | 69.9 M | 69.9 M | 69.9 M | 119 M | 119 M | 119 M | 119 M | 224 M | 224 M | 224 M | 224 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 224 M | -40.8 M | 43.6 M |
Gesamtes Eigenkapital anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtes Eigenkapital | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M |  USA |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |
 |
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
AbCellera Biologics
ABCL
|
967 M | $ 3.63 | -2.16 % | $ 1.08 B |  Canada |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
ADMA Biologics
ADMA
|
477 M | $ 16.54 | 0.98 % | $ 3.94 B | USA |
 |
Apellis Pharmaceuticals
APLS
|
370 M | $ 19.86 | -1.49 % | $ 2.51 B | USA |
 |
Aptorum Group Limited
APM
|
21.1 M | $ 0.83 | 4.19 % | $ 4.53 M | China |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
Burford Capital Limited
BUR
|
1.7 B | $ 8.37 | -2.11 % | $ 1.35 B | Britain |
 |
ANI Pharmaceuticals
ANIP
|
404 M | $ 76.53 | 0.57 % | $ 1.48 B | USA |
 |
Applied Therapeutics
APLT
|
-17.1 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
Cabaletta Bio
CABA
|
236 M | $ 3.43 | 5.54 % | $ 4.01 M | USA |
 |
Athersys
ATHX
|
16.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
648 M | $ 35.69 | 1.16 % | $ 3.71 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
954 M | $ 24.69 | 3.22 % | $ 3.02 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-6.9 M | $ 8.42 | 2.56 % | $ 36.4 M | USA |
 |
Axsome Therapeutics
AXSM
|
88.3 M | $ 164.08 | 0.02 % | $ 8.16 B | USA |
 |
CorMedix
CRMD
|
70.1 M | $ 7.12 | 3.04 % | $ 362 M | USA |
 |
Champions Oncology
CSBR
|
3.77 M | $ 6.0 | - | $ 82 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
70.1 M | $ 0.82 | 10.34 % | $ 5.52 M | USA |
 |
BridgeBio Pharma
BBIO
|
-2.09 B | $ 66.54 | 3.11 % | $ 12.7 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-7.76 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Denali Therapeutics
DNLI
|
1.23 B | $ 20.37 | 1.75 % | $ 3.35 B | USA |
 |
Edesa Biotech
EDSA
|
1.98 M | $ 4.27 | -1.84 % | $ 13.7 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
2.02 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
142 M | - | -7.31 % | $ 87 M | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Equillium
EQ
|
22.6 M | $ 1.75 | -1.13 % | $ 60.8 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | USA |